However, interfering directly with myeloid cell has proven to be efficacious in other diseases including psoriasis with multiple drugs targeting IL-23 (Guselkumab, Risankizumab, and Tildrakizumab) or IL-12 and IL-23 (Ustekinumab) (19), Crohn's disease and ulcerative colitis targeting IL-12 and IL-23 (Ustekinumab) (20), rheumatoid arthritis targeting IL-1 (Anakinra) (21), systemic juvenile idiopathic arthritis targeting IL-1β (Canakinumab) (22), and many others. Here, IL1B is linked to psoriasis.